Seeking to expand its strategic footprint, Regeneron (REGN) Pharmaceuticals will provide access to its technology to a small company that has big hopes of discovering medicines to prevent and treat hearing loss. And in exchange, Regeneron is taking an undisclosed equity stake and is slated to receive royalties from any drugs that might one day reach medicine chests.

The deal with Decibel Therapeutics, a privately held company that was launched two years ago, marks only the second time that Regeneron has reached such an arrangement with a preclinical-stage company to discover and develop medicines. Last year, Regeneron reached a similar arrangement with Adicet Bio to develop immune cell therapeutics, although an equity position was not part of that deal.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Let’s hope this cures tinnitus. Causes major ringing and balance trouble for millions. All the best.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy